Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study. (23rd June 2014)

• Record Type: Journal Article
• Authors: Eom, Ki-Seong; Kim, Seok Jin; Lee, Je-Jung; Suh, Cheolwon; Kim, Jin Seok; Yoon, Sung-Soo; Kim, Byung Soo; Kang, Hye Jin; Choi, Young Jin; Kim, Chul Soo; Kim, Yang Soo; Kwak, Jae-Yong; Kim, Yoo Jin; Joo, Young Don; Mun, Yeung-Chul; Jo, Deog Yeon; Park, Joon Seong; Park, Chi-Young; Kim, Sung-Hyun; Min, Chang-Ki
• Other Names: Lee Dong Soon Academic Editor.
• Is Part Of: BioMed research international. Volume 2014(2014)
• Publication Date: 2014-06-23
• Subjects: Medicine -- Periodicals; Biology -- Periodicals; Biotechnology -- Periodicals; Life sciences -- Periodicals; 610.5
• DOI: 10.1155/2014/245247
• Languages: English
• ISSNs: 2314-6133

Abstract

Abstract : We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma cell myeloma (PCM) in bone resorption and formation via bone turnover markers. A total of 104 patients received at least 1 cycle of bortezomib. Most of them had advanced disease (n = 89 ). Among them, 75 patients completed 4 cycles of treatment. Most of the patients (81.7%) were treated in combination with steroid. After the 4th cycle treatment, 47 of 75 patients achieved CR, nCR, VGPR, and PR (64.4%), while 26 patients achieved less than PR (35.6%). The proportion of patients who achieved ≥ PR increased as patients received more treatment cycles, reaching 90% after the 8th cycle. DKK-1 levels decreased significantly posttreatment. Bone formation markers (bALP and OC) and osteoclast regulator such as sRANKL also decreased significantly. These findings were observed primarily in patients who received steroid and who had a longer disease duration. While sRANKL demonstrated significant reduction posttreatment, osteoprotegerin (OPG) level did not significantly change posttreatment, resulting in a decreased sRANKL/OPG ratio (P = 0.037 ). In conclusion, our clinical data suggest that treatment with bortezomib and steroid may rearrange the metabolic balance between osteoblast and osteoclast activities in PCM.